title: Nanobody-based cancer therapy of solid tumors.
abstract: The development of tumor-targeted therapies using monoclonal antibodies has been successful during the last 30 years. Nevertheless, the efficacy of antibody-based therapy is still limited and further improvements are eagerly awaited. One of the promising novel developments that may overcome the drawbacks of monoclonal antibody-based therapies is the employment of nanobodies. Current nanobody-based therapeutics can be divided into three different platforms with nanobodies functioning as: receptor antagonists; targeting moieties of effector domains; or targeting molecules on the surface of nanoparticles. In this article, we describe factors that affect their performance at three different stages: their systemic circulation upon intravenous injection; their extravasation and tumor penetration; and, finally, their interaction with target molecules.
authors.affiliation: Division of Cell Biology, Department of Biology, Science Faculty, Utrecht University, Padualaan 8, 3584CH Utrecht, The Netherlands.
authors.forename: Marta
authors.initials: M
authors.lastname: Kijanka
authors.forename: Bram
authors.initials: B
authors.lastname: Dorresteijn
authors.forename: Sabrina
authors.initials: S
authors.lastname: Oliveira
authors.forename: Paul M P
authors.initials: PM
authors.lastname: van Bergen en Henegouwen
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D061905:Single-Domain Antibodies / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061905:Single-Domain Antibodies
keywords: VHH; cancer; delivery; nanobody; single-domain antibody; therapy